Kyongbo Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 1.88%

Kyongbo Pharmaceutical Co Ltd (214390) has an Asset Resilience Ratio of 1.88% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kyongbo Pharmaceutical Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩6.91 Billion
≈ $4.68 Million USD Cash + Short-term Investments

Total Assets

₩367.57 Billion
≈ $249.10 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Kyongbo Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Kyongbo Pharmaceutical Co Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Kyongbo Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 214390 long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩6.91 Billion 1.88%
Total Liquid Assets ₩6.91 Billion 1.88%

Asset Resilience Insights

  • Limited Liquidity: Kyongbo Pharmaceutical Co Ltd maintains only 1.88% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Kyongbo Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Kyongbo Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for Kyongbo Pharmaceutical Co Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Kyongbo Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.26% ₩820.00 Million
≈ $555.70K
₩319.54 Billion
≈ $216.55 Million
-0.45pp
2024-12-31 0.70% ₩2.00 Billion
≈ $1.36 Million
₩283.89 Billion
≈ $192.39 Million
+0.38pp
2023-12-31 0.33% ₩870.00 Million
≈ $589.59K
₩266.31 Billion
≈ $180.47 Million
-0.03pp
2022-12-31 0.36% ₩870.00 Million
≈ $589.59K
₩240.54 Billion
≈ $163.01 Million
+0.85pp
2021-12-31 -0.49% ₩-1.16 Billion
≈ $-786.85K
₩236.98 Billion
≈ $160.60 Million
-4.26pp
2020-12-31 3.77% ₩9.54 Billion
≈ $6.47 Million
₩253.24 Billion
≈ $171.62 Million
+4.21pp
2019-12-31 -0.44% ₩-1.05 Billion
≈ $-713.64K
₩237.82 Billion
≈ $161.17 Million
+0.27pp
2018-12-31 -0.71% ₩-1.58 Billion
≈ $-1.07 Million
₩221.62 Billion
≈ $150.19 Million
-0.07pp
2017-12-31 -0.64% ₩-1.32 Billion
≈ $-895.45K
₩204.87 Billion
≈ $138.84 Million
--
pp = percentage points

About Kyongbo Pharmaceutical Co Ltd

KO:214390 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$87.65 Million
₩129.34 Billion KRW
Market Cap Rank
#19768 Global
#1017 in Korea
Share Price
₩5410.00
Change (1 day)
+0.56%
52-Week Range
₩4945.00 - ₩8550.00
All Time High
₩19100.23
About

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more